Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAA50 | Q9GZZ1 | 2/20 | 1.00 |
| ▸ | CHAT | P28329 | 2/20 | 0.87 |
| ▸ | EP300 | Q09472 | 3/20 | 0.86 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.86 |
| ▸ | AURKA | O14965 | 2/20 | 0.86 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.86 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29761309 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL4356277 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29518048 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL6086 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL17656841 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL9995362 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL31126614 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL19018640 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL14593550 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA | |
| SCHEMBL29761307 | 1.00 | NAA50 (1.00) | NAA50CHATEP300KAT5AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987602-B2 | Malonate transporters | CB THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20240026392-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | GINKGO BIOWORKS, INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20230383319-A1 | ITERATIVE PLATFORM FOR THE SYNTHESIS OF ALPHA FUNCTIONALIZED PRODUCTS | Gonzalez, Ramon (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230372411-A1 | Methods and Compositions for Treatment of Microbiome Associated Disorders | Pendulum Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-11802280-B2 | Enzyme for synthesizing hydroxyl acetaldehyde and/or 1,3-dihydroxyacetone by catalyzing formaldehyde, and applications thereof | TIANJIN INSTITUTE OF INDUSTRIAL BIOTECHNOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2023-10-31 | — | — | US | disclosed |
| US-20230340446-A1 | BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS | GINKGO BIOWORKS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-11781120-B2 | Biosynthesis of polyketides | Gonzalez, Ramon (US) | 2023-10-10 | — | — | US | disclosed |
| US-11697830-B2 | Iterative platform for the synthesis of alpha functionalized products | Gonzalez, Ramon (US) | 2023-07-11 | — | — | US | disclosed |
| US-11692207-B2 | Enzymatic methods for butanol production | NEWPEK S.A. DE C.V. (MX) | 2023-07-04 | — | — | US | disclosed |
| US-20230183761-A1 | BIOCATALYTIC METHOD FOR THE CONTROLLED DEGRADATION OF TERPENE COMPOUNDS | FIRMENICH SA (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20120003233-A1 | HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20120004260-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY IODO-NITROBENZAMIDE COMPOUNDS AND METHODS OF TREATMENT THEREOF | BIPAR SCIENCES, INC. (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110243855-A1 | METHOD AND IMAGING MEDIUM FOR USE IN THE METHOD | GE HEALTHCARE LIMITED (GB) | 2011-10-06 | — | — | US | disclosed |
| US-20110229958-A1 | Host Cells for Production of Isoprenoid Compounds | Amyris, Inc. | 2011-09-22 | — | — | US | disclosed |
| US-20110217412-A1 | CHOLESTEROL LOWERING SUPPLEMENT AND LOW CHOLESTEROL EGG PRODUCED BY USING THE SAME | JINIS BIOPHARMACEUTICALS CO. (KR) | 2011-09-08 | — | — | US | disclosed |
| US-20110212954-A1 | ALPHA-LIPOIC ACID DERIVATIVES AND THEIR USE IN DRUG PREPARATION | ISTITUTO BIOCHIMICO NAZIONALE SAVIO S.R.L. (IT) | 2011-09-01 | — | — | US | disclosed |
| WO-2011087821-A2 | MICROBIAL PRODUCTION OF MULTI-CARBON CHEMICALS AND FUELS FROM WATER AND CARBON DIOXIDE USING ELECTRIC CURRENT | UNIVERSITY OF MASSACHUSETTS (US) | 2011-07-21 | — | — | WO | disclosed |
| US-20110033387-A1 | METHOD OF DETERMINATION OF PDH ACTIVITY AND IMAGING MEDIA FOR USE IN SAID METHOD | GE HEALTHCARE LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20110000125-A1 | PRODUCTION OF FATTY ALCOHOLS WITH FATTY ALCOHOL FORMING ACYL-COA REDUCTASES (FAR) | CODEXIS, INC. (US) | 2011-01-06 | — | — | US | disclosed |
| US-20090186358-A1 | Pathway Analysis of Cell Culture Phenotypes and Uses Thereof | WYETH (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372411-A1 | Methods and Compositions for Treatment of Microbiome Associated Disorders | FABP2, FADS1, ELOVL1 | NAA50 948/4885CHAT 514/4885EP300 1831/4885 |
| US-20120003233-A1 | HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR | DGAT2, DGAT1, SOAT2 | NAA50 555/4885CHAT 2397/4885EP300 2563/4885 |
| US-20110033387-A1 | METHOD OF DETERMINATION OF PDH ACTIVITY AND IMAGING MEDIA FOR USE IN SAID METHOD | PC, PDHB, PDHA2 | NAA50 1710/4885CHAT 755/4885EP300 1440/4885 |
| US-20110243855-A1 | METHOD AND IMAGING MEDIUM FOR USE IN THE METHOD | ACADM, NEFM, RXFP3 | NAA50 153/4885CHAT 56/4885EP300 1293/4885 |
| US-20110212954-A1 | ALPHA-LIPOIC ACID DERIVATIVES AND THEIR USE IN DRUG PREPARATION | ALOX12, ALOX15, ALOX15B | NAA50 1078/4885CHAT 1628/4885EP300 3470/4885 |
| US-20110000125-A1 | PRODUCTION OF FATTY ALCOHOLS WITH FATTY ALCOHOL FORMING ACYL-COA REDUCTASES (FAR) | FAR1, ACADM, FASN | NAA50 175/4885CHAT 1813/4885EP300 1194/4885 |
| US-20120004260-A1 | INHIBITION OF FATTY ACID SYNTHESIS BY IODO-NITROBENZAMIDE COMPOUNDS AND METHODS OF TREATMENT THEREOF | FASN, PARP12, PARP2 | NAA50 963/4885CHAT 4567/4885EP300 1186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.